3 Firms Forge Blackstone's $2B Alnylam Pharma Investment
The Blackstone Group on Monday agreed to inject as much as $2 billion into Alnylam Pharmaceuticals Inc. to help the Massachusetts-based biotechnology company advance treatments for cardiovascular and other diseases, in...To view the full article, register now.
Already a subscriber? Click here to view full article